Status:
COMPLETED
Olanzapine for the Prevention of Postoperative Nausea and Vomiting
Lead Sponsor:
Amani Hassan Abdel-Wahab
Conditions:
Postoperative Nausea
Eligibility:
FEMALE
18-50 years
Phase:
PHASE1
PHASE2
Brief Summary
Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an e...
Detailed Description
Aim of the Research, to compare the effects of oral 10 and 5 mg Olanzapine for the Prevention of Postoperative Nausea and Vomiting
Eligibility Criteria
Inclusion
- ASA I and II patients
- undergoing ambulatory laparoscopic gynecologic surgery with general anesthesia
- patients have at least two of the four Apfel risk factors for PONV2
- Lack of history of psychiatric and psychotic illnesses.
Exclusion
- ASA III and ≥ IV patients
- Psychological diseases
- History of chemotherapy
- have a pre-existing vestibular disorder or history of dizziness or preexisting nausea or vomiting in the 24 h before surgery, or were being treated with regular antiemetic therapy including systemic corticosteroids.
Key Trial Info
Start Date :
March 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04718727
Start Date
March 15 2021
End Date
February 1 2023
Last Update
March 9 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university hospitals
Asyut, Assiut Governorate, Egypt, Egypt, 715715
2
Assiut university
Asyut, Egypt